Skip to content
Alligator Bioscience

Alligator Bioscience

Svenska
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • ADC-1013
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • ATOR-1144
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors and collaborators
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • Swedish
Start > Investors > Financial reports
  • Share and shareholders
  • Calendar
  • Analysts
  • IPO
  • Financial reports
    • Annual reports
    • Interim reports
  • Presentations

Financial reports

201820172016

  • 12 July, 2018 - Interim Report January - June 2018 PDF
  • 26 April, 2018 - Interim report January - March 2018 PDF
  • 16 February, 2018 - Full Year Report 2017 PDF

  • 25 October, 2017 - Interim Report January-September 2017 PDF
  • 23 August, 2017 - Interim Report January-June 2017 PDF
  • 2 May, 2017 - Interim Report January-March 2017 PDF
  • 22 March, 2017 - Annual Report 2016 PDF
  • 17 February, 2017 - Full Year Report 2016 PDF

  • 14 November, 2016 - Interim Report January-September 2016 PDF

Financial reports

  • 2018
  • 2017
  • 2016
    • 26 Oct 2018 Alligator Bioscience AB Interim Report January-September 2018
    • 12 Jul 2018 Alligator Bioscience AB Interim Report January-June 2018
    • 26 Apr 2018 Alligator Bioscience AB Interim Report January-March 2018
    • 22 Mar 2018 Alligator Bioscience’s Annual Report 2017 published
    • 16 Feb 2018 Full Year Report 2017
    • 25 Oct 2017 Interim Report January-September 2017
    • 25 Oct 2017 Alligator Bioscience AB Interim Report January-September 2017
    • 23 Aug 2017 Interim Report January-June 2017
    • 23 Aug 2017 Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017
    • 02 May 2017 Interim Report January-March 2017
    • 02 May 2017 Alligator Bioscience AB Interim report January-March 2017
    • 22 Mar 2017 Alligator Bioscience Annual Report for 2016 published
    • 17 Feb 2017 Full Year Report 2016
    • 17 Feb 2017 Alligator Bioscience AB Full Year 2016 Report
    • 14 Nov 2016 Interim Report January-September 2016
    • 22 Mar 2016 Annual Report 2016

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 286 4280

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB